DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.
DRG and its group companies would like to inform you that we have updated our website privacy policy.
AcknowledgeIf you didn't find what you were looking for, try again!
Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous...
In DRG Blog/ September, 2019The following is an excerpt from the eBook RNA-based Therapies: Takeaways and Best Practices for Strategy Planning Although no RNA therapies are...
In DRG Blog, Drug Watch/ February, 2019A history of Evenity's development, and the wider implications of the FDA advisory committee's decision to recommend the approval of Evenity. The...
In DRG Blog, Drug Watch/ February, 2019The following is an excerpt from the eBook Checkpoint Inhibitors: Takeaways and Best Practices for Strategic Planning It’s very clear that the...
In DRG Blog, Drug Watch/ January, 2019Topics of discussion at the annual ACR/ARHP in October 2018 The annual meeting of the American College of Rheumatology/American Rheumatology Health...
In DRG Blog, Drug Watch/ December, 2018Introduction: Major depressive disorder (MDD) is a highly prevalent condition, affecting approximately 42 million people in the G7 (France, Germany...
In DRG Blog, Drug Watch/ November, 2018PARP inhibitors have generated huge excitement with their recent approvals in ovarian and breast cancer, these agents are making a meaningful...
In DRG Blog, Drug Watch/ October, 2018Does the future market value for gastroesophageal cancer reflect the effectiveness of emerging treatments? Key findings: In a new report from...
In DRG Blog, Drug Watch/ October, 2018How will emerging microbiome-based therapies impact disease markets, especially in gastrointestinal diseases? Key Findings: Research on the human...
In DRG Blog, Drug Watch/ October, 2018Will New Generics make the Cost of care Affordable? The cost of care for HIV patients continues to increase year over year, which combined with a...
In DRG Blog, Drug Watch/ October, 2018The PROs and CONS of Prescription Weight Loss Medications World Obesity Day is on October 11, and it is a timely reminder of the obesity epidemic...
In DRG Blog, Drug Watch/ October, 2018The human microbiome is composed of diverse populations that include bacteria, fungi, bacteriophages and viruses, and it is unique to each...
In DRG Blog, Drug Watch/ October, 2018What are the most important factors to consider when forecasting the launch of generic Xeljanz? Pfizer’s Xeljanz was the first Janus kinase (Jak...
In DRG Blog, Drug Watch/ September, 2018How will emerging SMA therapies address longstanding unmet needs, and where will remaining market opportunies lie? Key findings: Biogen/Ionis’s...
In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018How Safe will be Safe Enough for Regulators and Payers? In August 2018, FDA Commissioner Scott Gottlieb provided an update to the ongoing efforts...
In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018Microbiome-based therapies, which aim to modify the bacterial ecosystem that colonizes the human body, have been a hot area of research for the...
In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018Interstitial cystitis, a urological disorder that is more formally known as interstitial cystitis/bladder pain syndrome (ICBPS), is characterized...
In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018“Showing additional CV benefits is important for obesity therapies. It will hopefully remove some of the stigma against these drugs as being...
In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018Continuing in tradition, this year’s European Society of Cardiology (ESC) Congress, which was held during August 25-29 in Munich, again witnessed...
In DRG Blog, Drug Watch, Niche and Rare Disease/ August, 2018Hyperkalemia describes abnormally elevated levels of serum potassium, a complication that occurs frequently among patients with renal insufficiency...
In DRG Blog, Drug Watch, Niche and Rare Disease/ August, 2018Don’t forget to attend on Jan. 19!